340 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
AGN Allergan plc. $184.29 $62.56B N/A
Article Searches
Markets Climb Amid Solid Q4 Earnings http://www.zacks.com/stock/news/249222/markets-climb-amid-solid-q4-earnings?cid=CS-ZC-FT-249222 Feb 13, 2017 - Market futures are very positive this morning, and continue to climb 20 minutes before the opening bell sounds.
Allergan Plc (AGN) Brenton L. Saunders on Q2 2016 Results - Earnings Call Transcript http://seekingalpha.com/article/3997329-allergan-plc-agn-brenton-l-saunders-q2-2016-results-earnings-call-transcript?source=feed_all_articles Aug 08, 2016 - Allergan Plc (NYSE:AGN)Q2 2016 Earnings CallAugust 08, 2016 8:30 am ETExecutivesLisa M. DeFrancesco - Vice President-Investor RelationsBrenton L. Saunders - President, Chief Executive Officer & Direct
5 Drug Stocks Reporting Q2 Earnings on Aug 8: AGN & More http://www.zacks.com/stock/news/227035/5-drug-stocks-reporting-q2-earnings-on-aug-8-agn-more?cid=CS-ZC-FT-227035 Aug 05, 2016 - As the Q2 earnings cycle draws to a close, the overall picture that has emerged does not appear as grim as we feared.
Teva (TEVA) Beats on Q2 Earnings & Revenues, Stock Gains http://www.zacks.com/stock/news/226946/teva-teva-beats-on-q2-earnings-revenues-stock-gains?cid=CS-ZC-FT-226946 Aug 05, 2016 - In addition to reporting better-than-expected results, Teva (TEVA) also closed the Actavis Generics deal and announced it will be acquiring Allergan's Anda business.
Allergan (AGN) Q2 Earnings: Will the Stock Disappoint? http://www.zacks.com/stock/news/226764/allergan-agn-q2-earnings-will-the-stock-disappoint?cid=CS-ZC-FT-226764 Aug 04, 2016 - Allergan's (AGN) Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is a negative 1.49% - will the stock disappoint?
Biogen (BIIB) Stock Surges 8% on Takeover Rumors http://www.zacks.com/stock/news/226424/biogen-biib-stock-surges-8-on-takeover-rumors?cid=CS-ZC-FT-226424 Aug 02, 2016 - Biogen (BIIB) stock jumped 8% on late-afternoon trading on Tuesday on rumors that the company could be bought out by either Allergan (AGN) or Merck (MRK), both large-cap pharmaceutical companies.
Teva (TEVA): Stock Likely to Beat on Earnings in Q2 Again? http://www.zacks.com/stock/news/226197/teva-teva-stock-likely-to-beat-on-earnings-in-q2-again?cid=CS-ZC-FT-226197 Aug 02, 2016 - Our proven model shows that Teva (TEVA) is likely to beat earnings this quarter because it has the right combination of two key ingredients.
What Awaits Boston Scientific (BSX) in Q2 Earnings? http://www.zacks.com/stock/news/224050/what-awaits-boston-scientific-bsx-in-q2-earnings?cid=CS-ZC-FT-224050 Jul 19, 2016 - Boston Scientific Corporation (BSX) is scheduled to report its second-quarter 2016 results before the opening bell on Jul 28.
Hologic (HOLX) Q3 Earnings: A Surprise in the Cards? http://www.zacks.com/stock/news/223915/hologic-holx-q3-earnings-a-surprise-in-the-cards?cid=CS-ZC-FT-223915 Jul 19, 2016 - Hologic (HOLX) has a Zacks Rank #2 (Buy) which along with a 0.00 % ESP makes surprise prediction difficult.
Illumina (ILMN) to Report Q2 Earnings: What's in the Cards? http://www.zacks.com/stock/news/223906/illumina-ilmn-to-report-q2-earnings-whats-in-the-cards?cid=CS-ZC-FT-223906 Jul 19, 2016 - Illumina (ILMN) has a Zacks Rank #4 (Sell), which along with an ESP of 0.00% makes surprise prediction difficult.

Pages: 1...2728293031323334

<<<Page 32>